Clinical-stage biopharmaceutical company Kyverna Therapeutics Inc. (KYTX) is advancing its neuroimmunology pipeline with multiple late-stage programs, including a registrational Phase 3 trial for KYV-101 in generalized myasthenia gravis or MG.
The trial, part of the broader KYSA-6 study, is expected to enroll about 60 adult patients and begin recruitment by the end of 2025. This pivotal study will evaluate KYV-101, a fully human, autologous CD19-directed CAR T-cell therapy, against standard-of-care treatment to demonstrate meaningful improvements in MG-ADL and QMG scores at 24 weeks.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com